Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing

By sjmartinez • September 22, 2024

Lee JM. Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing. J Thorac Cardiovasc Surg. 2024 Oct;168(4):1281-1288. doi: 10.1016/j.jtcvs.2024.03.034. Epub 2024 Apr 20. PMID: 38649111.

Tags: Adjuvant, immunotherapy, Lung cancer, neoadjuvant, NSCLC, Perioperative, Publications, Pulmonary, Critical Care & Sleep Medicine

When Is Enough Enough? Additional Evidence of the Power of Zero

Budoff MJ. When Is Enough Enough? Additional Evidence of the Power of Zero. Circ Cardiovasc Imaging. 2024 Dec 20:e017714. doi: 10.1161/CIRCIMAGING.124.017714. Epub ahead of print.[...]

Increased mortality from alcohol use disorder, alcohol-associated liver disease, and liver cancer from alcohol among older adults in the United States: 2000 to 2021

Danpanichkul P, Duangsonk K, Tham EKJ, Tothanarungroj P, Auttapracha T, Prasitsumrit V, Sim B, Tung D, Barba R, Wong RJ, Leggio L, Yang JD, Chen[...]

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM,[...]